Advanced Pharmacology Final ACTUAL EXAM ALL
QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% VERIFIED SOLUTIONS | UPDATED PER LATEST
GUIDELINES | GRADED A+
PART I — GENERAL & CLINICAL PHARMACOLOGY
1. Pharmacokinetics
Which pharmacokinetic process describes movement of a drug from the bloodstream into
tissues?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Answer: B. Distribution
Rationale: Distribution is the reversible movement of a drug from systemic circulation into
tissues and body fluids. It is influenced by blood flow, lipid solubility, protein binding, and tissue
permeability.
2. First-Pass Metabolism
Which route largely bypasses hepatic first-pass metabolism?
A. Oral
B. Sublingual
C. Enteral feeding tube
D. Rectal, always completely
Answer: B. Sublingual
,Rationale: Sublingual drugs enter systemic circulation directly through oral mucosa, largely
bypassing the gastrointestinal tract and hepatic first-pass metabolism.
3. Bioavailability
Bioavailability refers to:
A. The fraction of administered drug reaching systemic circulation unchanged
B. The amount of drug excreted in urine
C. The time required to eliminate a drug
D. The degree of protein binding
Answer: A
Rationale: Bioavailability represents the proportion of a drug dose that reaches systemic
circulation in active form.
4. Half-Life
A drug's half-life is the time required for:
A. The drug to begin working
B. Plasma concentration to decrease by approximately 50%
C. The drug to reach peak concentration
D. Complete elimination of the drug
Answer: B
Rationale: Half-life is the time required for plasma drug concentration to decline by 50%. It
helps determine dosing intervals and time to steady state.
5. Steady State
For most drugs administered repeatedly, approximately how long does it take to approach
steady state?
A. One half-life
B. Two half-lives
C. Four to five half-lives
D. Ten half-lives in every case
,Answer: C
Rationale: Most drugs approach approximately 94–97% of steady-state concentration after
about four to five half-lives.
6. Loading Dose
A loading dose is primarily used to:
A. Rapidly achieve a desired therapeutic concentration
B. Permanently increase drug clearance
C. Prevent all adverse effects
D. Reduce bioavailability
Answer: A
Rationale: A loading dose provides enough drug initially to reach therapeutic concentrations
more rapidly, particularly when a drug has a long half-life.
7. Volume of Distribution
A very large volume of distribution generally suggests that a drug:
A. Remains primarily within plasma
B. Is extensively distributed into tissues
C. Cannot cross membranes
D. Is completely protein-bound
Answer: B
Rationale: A large apparent volume of distribution indicates substantial movement of drug from
plasma into tissues or other compartments.
8. Protein Binding
Which patient is most vulnerable to increased free concentrations of a highly protein-bound
drug?
A. Patient with severe hypoalbuminemia
B. Patient with normal albumin
, C. Patient with increased muscle mass
D. Patient with mild dehydration only
Answer: A
Rationale: Low albumin can reduce binding sites for highly protein-bound drugs, increasing the
unbound pharmacologically active fraction.
9. CYP450 Enzyme Inhibition
A CYP450 inhibitor generally causes concentrations of a substrate drug to:
A. Increase
B. Decrease
C. Remain unchanged in every patient
D. Become completely inactive
Answer: A
Rationale: Enzyme inhibition decreases metabolism of substrate drugs, potentially increasing
plasma concentrations and toxicity.
10. CYP450 Induction
A CYP450 inducer generally causes concentrations of susceptible substrate drugs to:
A. Increase
B. Decrease
C. Become permanently toxic
D. Remain unchanged
Answer: B
Rationale: Enzyme induction increases metabolic activity and can reduce concentrations and
therapeutic effects of affected drugs.
PART II — AUTONOMIC & CARDIOVASCULAR PHARMACOLOGY
11. Beta Blockers
A patient taking a nonselective beta blocker should be monitored especially closely for:
QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% VERIFIED SOLUTIONS | UPDATED PER LATEST
GUIDELINES | GRADED A+
PART I — GENERAL & CLINICAL PHARMACOLOGY
1. Pharmacokinetics
Which pharmacokinetic process describes movement of a drug from the bloodstream into
tissues?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Answer: B. Distribution
Rationale: Distribution is the reversible movement of a drug from systemic circulation into
tissues and body fluids. It is influenced by blood flow, lipid solubility, protein binding, and tissue
permeability.
2. First-Pass Metabolism
Which route largely bypasses hepatic first-pass metabolism?
A. Oral
B. Sublingual
C. Enteral feeding tube
D. Rectal, always completely
Answer: B. Sublingual
,Rationale: Sublingual drugs enter systemic circulation directly through oral mucosa, largely
bypassing the gastrointestinal tract and hepatic first-pass metabolism.
3. Bioavailability
Bioavailability refers to:
A. The fraction of administered drug reaching systemic circulation unchanged
B. The amount of drug excreted in urine
C. The time required to eliminate a drug
D. The degree of protein binding
Answer: A
Rationale: Bioavailability represents the proportion of a drug dose that reaches systemic
circulation in active form.
4. Half-Life
A drug's half-life is the time required for:
A. The drug to begin working
B. Plasma concentration to decrease by approximately 50%
C. The drug to reach peak concentration
D. Complete elimination of the drug
Answer: B
Rationale: Half-life is the time required for plasma drug concentration to decline by 50%. It
helps determine dosing intervals and time to steady state.
5. Steady State
For most drugs administered repeatedly, approximately how long does it take to approach
steady state?
A. One half-life
B. Two half-lives
C. Four to five half-lives
D. Ten half-lives in every case
,Answer: C
Rationale: Most drugs approach approximately 94–97% of steady-state concentration after
about four to five half-lives.
6. Loading Dose
A loading dose is primarily used to:
A. Rapidly achieve a desired therapeutic concentration
B. Permanently increase drug clearance
C. Prevent all adverse effects
D. Reduce bioavailability
Answer: A
Rationale: A loading dose provides enough drug initially to reach therapeutic concentrations
more rapidly, particularly when a drug has a long half-life.
7. Volume of Distribution
A very large volume of distribution generally suggests that a drug:
A. Remains primarily within plasma
B. Is extensively distributed into tissues
C. Cannot cross membranes
D. Is completely protein-bound
Answer: B
Rationale: A large apparent volume of distribution indicates substantial movement of drug from
plasma into tissues or other compartments.
8. Protein Binding
Which patient is most vulnerable to increased free concentrations of a highly protein-bound
drug?
A. Patient with severe hypoalbuminemia
B. Patient with normal albumin
, C. Patient with increased muscle mass
D. Patient with mild dehydration only
Answer: A
Rationale: Low albumin can reduce binding sites for highly protein-bound drugs, increasing the
unbound pharmacologically active fraction.
9. CYP450 Enzyme Inhibition
A CYP450 inhibitor generally causes concentrations of a substrate drug to:
A. Increase
B. Decrease
C. Remain unchanged in every patient
D. Become completely inactive
Answer: A
Rationale: Enzyme inhibition decreases metabolism of substrate drugs, potentially increasing
plasma concentrations and toxicity.
10. CYP450 Induction
A CYP450 inducer generally causes concentrations of susceptible substrate drugs to:
A. Increase
B. Decrease
C. Become permanently toxic
D. Remain unchanged
Answer: B
Rationale: Enzyme induction increases metabolic activity and can reduce concentrations and
therapeutic effects of affected drugs.
PART II — AUTONOMIC & CARDIOVASCULAR PHARMACOLOGY
11. Beta Blockers
A patient taking a nonselective beta blocker should be monitored especially closely for:
